Successful Treatment for Hepatoblastoma in Trisomy 18: A Case Report

Kazuki Shirane,Ai Yoshimi,Takayuki Masuko,Daigo Kajikawa,Miki Toma,Hiroto Idesawa,Yugo Tsukada,Yusuke Yano,Keisuke Kato,Keiichi Motoyama,Nobuyoshi Asai,Koji Hirono,Tatsuo Kono,Haruo Otani,Junko Shiono,Isho Izumi,Toshihiro Yanai

DOI: https://doi.org/10.1097/mph.0000000000002788

2024-01-05

Journal of Pediatric Hematology/Oncology

Abstract:Children with trisomy 18 tend to develop hepatoblastoma. Since the introduction of appropriate management for organ malfunction, individuals with trisomy 18 have come to have a longer life expectancy. However, the predisposition to hepatoblastoma becomes a significant issue for the quality of a case. Here, we present a rare multifocal hepatoblastoma involving predominantly Couinaud segments 5 and 7 in a 10-month-old boy with trisomy 18. Though the first-line cisplatin monotherapy resulted in unsatisfactory tumor shrinkage, the second-line neoadjuvant chemotherapy administrating irinotecan and vincristine gave rise to significant tumor reduction in volume, leading to the completion of partial resection of the liver without the microscopic residual disease. The patient has been free from recurrence for 44 months. Because anatomical right hepatectomy can cause circulatory instability, including acute onset of pulmonary hypertension in trisomy 18 patients, physicians should balance treatment benefits and potential adverse effects. Our successful experience utilizing a combination of efficacious and less cardiotoxic neoadjuvant chemotherapy followed by the partial hepatectomy encourages physicians to treat a patient with trisomy 18 and tackle hepatoblastoma with a genetic background.

oncology,pediatrics,hematology